Exagen (NASDAQ:XGN) Releases Earnings Results, Hits Estimates

Exagen (NASDAQ:XGN) released its quarterly earnings results on Monday. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.20), RTT News reports. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. The business had revenue of $15.50 million during the quarter, compared to the consensus estimate of $14.55 million. During the same period in the previous year, the company posted ($0.19) EPS. Exagen updated its FY 2025 guidance to EPS.

Exagen Price Performance

Shares of XGN opened at $6.39 on Tuesday. The firm has a market capitalization of $114.94 million, a PE ratio of -6.66 and a beta of 1.50. The stock’s 50 day moving average is $4.30 and its two-hundred day moving average is $4.03. Exagen has a twelve month low of $1.35 and a twelve month high of $7.00. The company has a current ratio of 4.05, a quick ratio of 4.05 and a debt-to-equity ratio of 1.54.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. William Blair reiterated an “outperform” rating on shares of Exagen in a research report on Wednesday, March 12th. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 target price on shares of Exagen in a research note on Monday, January 13th.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).